Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
The Urologic Clinics of North America|December 6, 2006
Pregnancy and urinary diversionRichard E Hautmann, Bjoern G VolkmerWorld Journal of Urology|March 26, 2009
Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)Richard E Hautmann, Bjoern G Volkmer, Kilian GustWorld Journal of Urology|October 19, 2004
High-flow priapism: colour-Doppler ultrasound-guided supraselective embolization therapyGeorg Bartsch, Rainer Kuefer, Oliver Engel, et al.World Journal of Urology|November 21, 2008
Neobladder formation after pelvic irradiationRichard E Hautmann, Robert de Petriconi, Bjoern G VolkmerThe Journal of Urology|April 19, 2011
25 years of experience with 1,000 neobladders: long-term complicationsRichard E Hautmann, Robert C de Petriconi, Bjoern G VolkmerThe Journal of Urology|July 21, 2010
Lessons learned from 1,000 neobladders: the 90-day complication rateRichard E Hautmann, Robert C de Petriconi, Bjoern G VolkmerEuropean Urology|March 3, 2012
Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patientsRichard E Hautmann, Robert C de Petriconi, Christina Pfeiffer, et al.Clinical Rheumatology|July 22, 2005
Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinomaBjoern G Volkmer, Evelyn M Seidl-Schlick, Dietmar Bach, et al.The Journal of Urology|February 24, 2009
Oncological followup after radical cystectomy for bladder cancer-is there any benefit?Bjoern G Volkmer, Rainer Kuefer, Georg C Bartsch, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 14, 2020
Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunctionAmelie Hartmann, Maria Paparoupa, Bjoern G Volkmer, et al.Pageof 4